| アブストラクト | INTRODUCTION: Despite rising concerns regarding the safety of anti-obesity medications, there is a lack of comprehensive pharmacovigilance investigations utilising real-world data. We aimed to characterise the prevalence and seriousness of adverse drug events (ADEs) related to anti-obesity medications and to identify predictors associated with increased risk of serious adverse events (SAE), thereby conveying evidence on drug safety. METHODS: We conducted a cross-sectional analysis on ADE cases spontaneously reported to the Korea Adverse Event Reporting System Database (KIDS-KD). ADE reports pertaining to anti-obesity medications prescribed for overweight, obesity (International Classification of Disease, 10th revision (ICD-10) code E66) and abnormal weight gain (ICD-10 code E63.5) were included in the analysis. We performed a disproportionality to detect the association of the system organ class-based ADEs with their seriousness an individual's sex by estimating reporting odds ratios (RORs) and their 95% confidence intervals (CIs). We performed logistic regression to investigate factors that are substantially associated with increased SAE risks by estimating odds ratio (OR) and their 95% CIs. RESULTS: The most common causative anti-obesity medication was phentermine, followed by liraglutide. ADEs associated with psychiatric disorders (ROR = 1.734; 95% CI = 1.111-2.707), liver and biliary system disorders (ROR = 22.948; 95% CI = 6.613-70.635), cardiovascular disorders (ROR = 5.707; 95% CI = 1.965-16.574), and respiratory disorders (ROR = 4.567; 95% CI = 1.774-11.762) were more likely to be serious events. Additionally, men are more likely to experience ADEs related gastrointestinal disorders (ROR = 1.411) and less likely to have heart and rhythm disorders (ROR = 0.507). The risk of SAE incidences was positively correlated with being male (OR = 2.196; 95% CI = 1.296-3.721), dual or triple combination of anti-obesity medications (OR = 3.258; 95% CI = 1.633-6.501 and OR = 8.226; 95% CI = 3.046-22.218, respectively), and concomitant administration of fluoxetine (OR = 5.236; 95% CI = 2.218-12.365). CONCLUSIONS: Seriousness of anti-obesity medication-related ADEs differs among system-organ class, while sex-related differences in ADE profiles are also present. The predictors substantially increasing risk of SAE incidences include being male, having a higher number of concomitant medications (including multiple combination of anti-obesity medications), and concurrent use of fluoxetine. Nonetheless, further pharmacovigilance investigation and monitoring are needed to enhance awareness on ADEs induced by anti-obesity medications. |
|---|
| ジャーナル名 | Journal of global health |
|---|
| Pubmed追加日 | 2023/8/31 |
|---|
| 投稿者 | Choi, Yeo Jin; Choi, Chang-Young; Kim, Choong Ui; Shin, Sooyoung |
|---|
| 組織名 | Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, South;Korea.;Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul,;South Korea.;Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University,;Seoul, South Korea.;Department of Internal Medicine, Ajou University Medical Hospital, Suwon, South;Department of Pharmacy, College of Pharmacy, Ajou University, Suwon, South Korea.;Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou;University, Suwon, South Korea. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37651636/ |
|---|
